RESPIRE: The National Institute for Health Research's (NIHR) Global Respiratory Health Unit by Sheikh, Aziz et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESPIRE: The National Institute for Health Research's (NIHR)
Global Respiratory Health Unit
Citation for published version:
Sheikh, A, Campbell, H, Balharry, D, Baqui, AH, Bogaert, D, Cresswell, K, Cunningham, S, Dockerell, D, El
Arifeen, S, Fletcher, M, Grant, M, Shariff Ghazali, S, Habib, GMM, Hazir, T, Isaac, R, Juvekar, S, Khoo, EM,
McKinstry, B, Morris, A, Nair, H, Norrie, J, Nwaru, B, Pinnock, H, Robertson, D, Saha, SK, Salvi, S,
Schwarze, J, Simpson, C, Sridhar, D, Stoddart, A, Weller, D, Whyte, M, Worth, A, Williams, S, Yusuf, O,
Zumla, A & Rudan, I 2018, 'RESPIRE: The National Institute for Health Research's (NIHR) Global
Respiratory Health Unit' Journal of Global Health, vol. 8, no. 2, pp. 020314. DOI: 10.7189/jogh.08.020101
Digital Object Identifier (DOI):
10.7189/jogh.08.020101
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Global Health
Publisher Rights Statement:
This work is licensed under a Creative Commons Attribution 4.0 International License.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
E
D
IT
O
RI
A
L
CONTEXTUAL CONSIDERATIONS: THE NEED FOR RESPIRE
The National Institute of Health Research (NIHR) Global Health Research Unit on Respiratory Health 
(RESPIRE) aims to reduce morbidity and mortality from respiratory diseases globally, with an initial focus 
on South Asia where respiratory conditions account for around one in five of all deaths. This geographi-
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cally focused approach allows RESPIRE to develop a regional network of excellence in four South Asian 
countries, namely Bangladesh, India, Malaysia and Pakistan, though over time the intention is to extend 
the Unit’s activities. Interested colleagues from other countries are invited to contact RESPIRE via the web-
site (www.ed.ac.uk/usher/respire) which gives more information on the work of the Unit, and provides 
contact details on how to get involved and support RESPIRE’s goals in other countries.
In the 2017 Global Burden of Disease (GBD) study, lower respiratory tract infections (LRTI), chronic ob-
structive pulmonary disease (COPD), tuberculosis (TB) and lung cancer were all ranked among the top 
12 medical conditions (out of nearly 300) in terms of global premature mortality measured as Years of 
Life Lost (YLL) [1-5]. COPD was ranked 6th (female) and 9th (male) in terms of disability, measured as 
Years of Life with Disability (YLD) [1-5]. In fact, in 2016, COPD was the 3rd highest cause of death glob-
ally, claiming 3 million lives, while lung cancer (along with trachea and bronchial cancers) was the 6th 
highest [6]. LRTIs were ranked 4th, making them the most deadly set of communicable diseases, causing 
3 million deaths worldwide [6]. In 2017, in South Asia alone, just five respiratory conditions accounted 
for 14.4% of all Disability-Adjusted Life Years (DALYs; LRTIs, 4.9%; COPD, 4.6%; TB, 3.0%; asthma, 
1.4%; lung cancer, 0.5% of total DALYs) [7]. Furthermore, awareness of their relative importance is low 
and these conditions have not attracted the attention and priority they deserve from health systems, pol-
icy makers and funding agencies nationally, within the South Asia region, or indeed globally [5,8].
Despite this substantial morbidity and mortality from both communicable and non-communicable respi-
ratory conditions in low- and middle-income countries (LMICs), they are currently relatively neglected 
by global research funders. Much of this ill-health is preventable through bridging the ‘second transla-
tional gap’ [9]. In the target LMICs, this necessitates a detailed appreciation of local challenges – for ex-
ample, social stigma associated with diagnoses of asthma, limited appreciation of risk factors (eg, smok-
ing/biomass fuel exposure) and the role of self-management, the use of alternative therapies, high clinician 
workloads and limited continuity of care. Using these to develop innovative tools/solutions involves mo-
bilisation of local assets aligned with global opportunities.
The RESPIRE Collaboration recognises the value of achieving impact by adapting and/or culturally tailor-
ing interventions that have already been found to be effective in other populations. RESPIRE has launched 
implementation studies of adapted interventions in the context of acute LRTIs and chronic respiratory 
disorders. In the longer-term, they will be complemented by the development of novel interventions for 
areas where there is no available evidence from other contexts through initiating relevant underpinning 
work leading to definitive trials.
AIMS AND STRATEGIC GOALS OF RESPIRE
RESPIRE is dedicated to achieving a step-change in national and regional infrastructures and capacity in 
applied respiratory research. The specific aims are to develop into a world-leading Unit that will: (i) Map 
and collate continuing and emerging respiratory challenges; (ii) Prioritise existing evidence-based interven-
tions that have the potential to be adapted to reduce mortality and morbidity in LMICs; (iii) Support local 
adaptation and tailoring of interventions for deployment in low-resource environments and catalyse de-
velopmental work in areas of unmet need; (iv) Support local implementation efforts and evaluation of pro-
grammes of work; and (v) Identify the best delivery mechanisms for long-term delivery and scaling-up.
To achieve this, RESPIRE focuses on two programmes of research and three underpinning infrastructures 
or platforms. The first programme addresses the continuing challenge posed by acute infections such as 
pneumonia and respiratory syncytial virus (RSV), while the second programme addresses long-term non-
communicable diseases – in particular, asthma, COPD and lung cancer. These two research programmes 
are supported by an underpinning infrastructure of three cross-cutting platforms: (i) Stakeholder engage-
ment & governance (to work with partners in engaging a diverse multi-sectoral group in support of RE-
SPIRE activities); (ii) Training & capacity development (to increase the number of health professionals 
and researchers who are trained to undertake high quality research, including online courses, distance 
learning masters, PhD training, and training in research leadership and promotion); and (iii) Methodol-
ogy & data science (ensuring appropriate study designs are adopted and developing plans to maximise 
the uses that research data can be put to in safe and secure ways).
Coordinated from The University of Edinburgh, RESPIRE brings together a collaborative group of equal 
partners from the four countries in South Asia. Capacity and capability is being built in these countries to 
undertake research that is robust and widely relevant to progress the global respiratory health agenda, whilst 
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also being responsive to each country’s particular context and priorities. A specific focus is to address the 
problems of the poorest populations in these countries, wherever possible. RESPIRE also looks for up-to-
date scientific evidence to find ways to reduce deaths and illness caused by these respiratory conditions.
RESPIRE aims to introduce tailored solutions – such as supporting medical doctors and other health pro-
fessionals or community workers to deliver care through mobile phones (“mHealth”), and study the im-
pact these have. For problems where there is no relevant up-to-date scientific evidence on which to draw, 
the RESPIRE Unit searches for innovative strategies and interventions to reduce mortality and morbidity 
secondary to respiratory diseases using experimental study designs to find out if the new solutions are 
effective and represent good value for money. For interventions meeting these criteria, RESPIRE is work-
ing with partner organisations in South Asian countries towards sustainability and scalability of work 
done, to ensure that they can be provided in the longer term and extended to other areas.
Initially, RESPIRE is promoting shared understanding and developing effective, reciprocal and ethical 
working relationships; agreeing local research priorities and commencing adaptation projects in both re-
search programmes; identifying research gaps that require more underpinning work; and establishing 
working groups to develop new grant applications. In the medium-term, the Unit aims to increase capac-
ity and capability in undertaking applied implementation research; to submit collaborative follow-on 
grants; and to develop sustainability plans. Over the longer-term, RESPIRE aims to maximise the local, 
regional and global impact from the new knowledge and experience generated by its programmes; release 
joint publications in top-tier journals; communicate findings to professionals, policymakers and the gen-
eral population; apply learning to embrace new clinical contexts and expand partnerships; and secure 
follow-on grants to sustain RESPIRE activities into the future, in order to reduce morbidity and mortality 
linked to respiratory disorders.
NATIONAL AND INTERNATIONAL COLLABORATIONS
RESPIRE also works with other countries across Asia and Africa, with a vision of scaling-up efforts in due 
course. RESPIRE investigators currently lead global research networks on respiratory conditions, which 
include more than 50 research groups, forming enduring and trusting relationships leading to data shar-
ing, co-authorship of publications and joint meetings with high levels of LMIC participation, such as Re-
spiratory Syncytial Virus Global Epidemiology Network (RSV GEN) [10].
RESPIRE maintains strong relationships with The World Bank, United Nations International Children's 
Emergency Fund (UNICEF), United States Agency for International Development (USAID), Global Alli-
ance against Chronic Diseases, The Joint United Nations Programme on HIV and AIDS (UNAIDS) and 
The United Nations Population Fund (UNFPA). Its investigators serve on The World Health Organization 
(WHO) Expert Groups for Air pollution, Childhood pneumonia, Influenza and RSV. RESPIRE also enjoys 
strong relationships with charitable sector partners, such as Asthma UK, the British Lung Foundation, 
Bill and Melinda Gates Foundation, Save the Children, The Wellcome Trust as well as professional com-
munities such as the International Primary Care Respiratory Group (IPCRG). Its investigators are Editors-
in-Chief of “Nature Partner Journals: Primary Care Respiratory Medicine” and “Journal of Global Health”. 
IPCRG’s network is facilitating dissemination to other LMICs.
RESPIRE investigators have close working relationships with the Respiratory Industry Group of the As-
sociation of British Pharmaceutical Industries (ABPI) and TATA communications, the latter providing mo-
bile connectivity in over 600 networks, including all partner countries.
TWO PROGRAMMES OF RESEARCH
RESPIRE harbours research programmes in: (i) Acute LRTIs – including bronchiolitis, bronchitis and 
pneumonia; and (ii) Chronic respiratory disorders – including asthma, COPD, and lung cancer. Specific 
local projects have been prioritised in association with LMIC partners. RESPIRE is also open to playing a 
responsive role in the context of pandemics (eg, influenza), antimicrobial stewardship, and data science/
security through, for example, shifting resources/staff, to convene expert working groups.
By focusing on high prevalence and high burden, neglected conditions that affect the poorest populations, 
RESPIRE has identified areas of likely growth. There are opportunities to expand to other respiratory pri-
orities, such as air quality, occupational lung disorders and respiratory co-morbidities.
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Programme 1: Acute lower respiratory tract infectious disorders
RESPIRE programme 1 brings together some of the world leaders in paediatric LRTI research both from 
the RESPIRE partner countries in South Asia as well as in the UK. The Unit aims to involve other leading 
international leaders from outwith RESPIRE with significant expertise on specific research questions to 
collaborate and advise on specific projects. This programme therefore aims to: (i) initiate projects to as-
sess scaling-up and deliverability of affordable and locally adaptable interventions with proven effective-
ness against priority concerns relating to childhood acute LRTI in the four RESPIRE countries; (ii) con-
duct multi-country implementation and experimental studies to inform development of new patient 
management guidelines that can feed into evidence base for the WHO; (iii) develop new interventions or 
techniques through small scale projects to serve as proofs of concept for later larger scale trials against 
complex intractable clinical challenges relating to management of paediatric acute LRTIs.
Programme 2: Chronic respiratory disorders
There are four main objectives within Programme 2 which are addressed by a range of research projects 
and PhD studentships across all of the partner countries: (i) to identify and assess the burden of chronic 
respiratory disease (CRD) in the four partner countries; (ii) to develop and evaluate interventions to im-
prove the management of COPD (and other CRD); (iii) to map the seasonal and geographic allergen load 
and impact of triggers for asthma; and (iv) to develop tailored approaches to providing supported self-
management for asthma.
The primary aim of the major theme on CRDs is to identify the prevalence of COPD and/or asthma, but 
also other CRDs, amongst adults in Bangladesh, India, Malaysia and Pakistan. RESPIRE also aims to iden-
tify risk factors, assess the burden of disease and health care utilisation associated with the development 
of these conditions. An additional aim is to establish a RESPIRE cohort of people for on-going monitor-
ing and recruitment to future research.
CRDs in low resource settings are neglected and often poorly diagnosed which leads to missed opportu-
nities for early initiation of treatment, and poor patient pathways. A number of projects will develop and 
evaluate interventions to improve the management of asthma, COPD and other CRDs identified in the 
RESPIRE prevalence survey, optimising the potential of the RESPIRE cohort.
THREE UNDERPINNING PLATFORMS
The purpose of RESPIRE platforms is to improve capacity to work with and mobilise national and inter-
national partners who can improve the outcomes of the research in terms of its appropriateness, its impact 
on health systems and individuals and its sustainability. Capacity and capability building by training and 
development is key to increasing the number of health professionals and researchers who are trained to 
undertake high quality research for the future. Finally, methodological rigour and world-leading data sci-
ence expertise is harnessed to maximise the uses that research data can be put to in safe and secure ways.
Platform I: Stakeholder engagement and governance
Effective stakeholder engagement requires a context-specific understanding and analysis of stakeholders, 
and action planning, drawing on the best available evidence. There can also be specific ethical and po-
litical challenges in LMICs relating to poverty, equity and the current norms and beliefs about public em-
powerment that need to be addressed sensitively.
RESPIRE stakeholders include donors, policy makers, media, workforce including professional societ-
ies and health care employers, other academic departments, citizens, patients and carers. Stakeholders 
may be involved throughout the research process, including problem identification, research design 
and planning, research implementation including recruitment, participatory data collection, analysis 
and interpretation, knowledge translation and implementation and review and adaptation for future 
studies [11,12,13].
The main aims are: (i) to agree the purposes of the engagement and who should be engaged and when; 
(ii) to map stakeholders using standard tools; (iii) to analyse the power and impact of each stakeholder 
at the key phases of each research project; (iv) to develop feasible engagement action plans based on cur-
rent relationships, trust and priorities and to include these in research protocols; (v) to identify learning 
needs in the team and to address these effectively; and (vi) to identify learning needs in the stakeholders 
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and suggest to the RESPIRE’s Unit Management Committee (UMC) how these might be addressed through 
massive online open courses (MOOCs) or other resources.
At the launch, RESPIRE initiated a process with each country team to undertake stakeholder mapping 
and analysis as a forerunner to developing stakeholder engagement planning and action. It led to some 
important discussions between team members about different perspectives and relationships. RESPIRE 
will continue to raise awareness and promote the importance of stakeholder engagement among the coun-
try partners.
Future plans include bolstering the role of Patient and Public Involvement (PPI) in global health research. 
PPI is increasingly becoming standard practice in UK health research and there is a need to ensure the 
work of RESPIRE remains relevant to the communities in which it works. In addition to identifying ways 
to embed PPI within the research, it will also be important to explore the use of more community devel-
opment approaches to ensure the patient voice is heard.
The academic questions in global governance that complement RESPIRE as a whole are: (i) what is the 
health system in each of these countries, and how does the current health system respond to respiratory 
conditions across the life course?; (ii) what changes would need to be made at the health system, and at 
which level, to incorporate the evidence on interventions coming out of RESPIRE projects, what would 
these cost, and who would pay for these?; (iii) what is the role of donors and international organisations 
in each of these countries, and what evidence are they demanding in order to tailor their financing pack-
ages and mechanisms towards the interventions highlighted by RESPIRE. These issues will be very im-
portant to elucidate in detail so that study findings can be properly interpreted and their applicability in 
other South Asian settings considered for intervention scale-up.
Platform II: Capacity and capability development
There is a need to develop all levels of research capacity in partner LMICs, ranging from introductory 
courses in research methods to post-graduate training and courses aimed at executive leaders.
MOOCs and Masters
RESPIRE builds on a track-record in The University of Edinburgh of delivering research training oppor-
tunities tailored to different needs and contexts. This includes running (MOOCs), face-to-face and dis-
tance learning, certificate and masters level courses, and training international PhD students from LMICs. 
RESPIRE aims to develop specialist MOOCs in health services research and respiratory disorders to foster 
a peer-to-peer learning community. Through an internal scholarship programme, which is a part of its 
Commonwealth Commission commitments, RESPIRE can provide a limited number of places in the dis-
tance-learning Masters courses, eg, on Clinical Trials, Master of Family Medicine, Infectious Diseases, 
Global eHealth and eMaster of Public Health. Students are selected through a competitive process in each 
of the partner countries, which includes assessment of the alignment of dissertation project with RESPIRE 
priorities.
PhDs
RESPIRE is supporting PhD candidates from the four partner countries at The University of Edinburgh, 
whilst enabling them to carry out their primary research activities in their home countries. The students 
were selected through a competitive process to join the University’s existing cohort of international PhD 
students. Edinburgh's Global Health Academy (GHA) provides postgraduate students and visiting fellows 
with links to a range of teaching resources and opportunities, linking them to the GHA community of 
practice, which includes a wide alumni network of graduates living in LMICs. In the first RESPIRE-fund-
ed PhD student cohort, 10 PhD students commenced their studies from 1st April 2018, following the in-
duction week from 26th-30th March 2018 to prepare them for their PhD studies. Six of the PhDs are nest-
ed within RESPIRE projects, whilst four are stand-alone projects, closely aligned to the RESPIRE research 
priorities. Each PhD student is supervised by at least two Edinburgh-based supervisors and at least one 
partner country-based supervisor. They all investigate research questions relating to one of the two pro-
grammes of the RESPIRE Unit.
Topics approved for the first cohort of RESPIRE PhD students include development and pilot testing of 
an intervention on lung cancer and chronic respiratory disease in a rural community, assessing the feasi-
bility of using a well-established teleconsultation facility (Micro-Health Centre -MHC) in management of 
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COPD and asthma in a remote rural area, studying care-seeking practices of and barriers to care-seeking 
for pneumonia in children aged less than 5 years in rural areas, studying culturally tailored school-based 
interventions for childhood asthma, developing and piloting an ICT-based intervention for adult asthma 
with limited health literacy to improve asthma self-management, implementation research on introduc-
ing pulse oximetry with routine Integrated Management of Childhood Illness (IMCI) services at health 
facilities, enhancing access to pulmonary rehabilitation through implementation research, exploring long-
term effects of RSV infection in early childhood, community use of digital auscultation to improve diag-
nosis of paediatric pneumonia in rural areas, and mHealth for improving care.
Research leadership and in-country training
RESPIRE will provide executive research leadership training, a bespoke programme aimed at respiratory 
research leaders in partner LMICs with a view to networking regionally and with UK and international 
investigators. Training is focused on developing underpinning research infrastructures and applied respi-
ratory research capacity in their countries. This capacity building includes use of decision-making tools 
that were developed at The University of Edinburgh (eg, the Child Health and Nutrition Research Initia-
tive (CHNRI) method [14-16]) in collaboration with international agencies. Research leaders are taught 
how to apply these tools using the data platforms in their own country and how to communicate the 
identified priorities to policymakers. RESPIRE will also provide focussed ‘Research Schools’ to address 
specific research training needs prioritised by the Partners, in each of their own countries. In this way 
RESPIRE hopes to reach a broad audience encapsulating clinicians, health care providers, community 
health workers etc, as well as academics and researchers.
Platform III: Methodology and data science
This platform is developing partner capacity and provide expertise on methodology and data science re-
quired to underpin the long-term delivery of interventions.
In a collaborations with RESPIRE partners, methodological support is provided which is tailored to achieve 
country and context-specific realisation of the short-, medium- and long-term goals of RESPIRE. This in-
cludes methodological support that addresses the specific needs of the individual projects – in terms of 
design, conduct, analysis and reporting; and including input from statisticians, epidemiologists, health 
economists, qualitative researchers, health psychologists, and patient experts. The Unit is developing a 
Methodology Academy which includes methodologists who are involved in RESPIRE projects, from Ed-
inburgh, Bangladesh, India, Malaysia and Pakistan. Importantly, it is not restricted to just those funded 
within RESPIRE, so the Academy will encourage participation and input from a wide range of method-
ologists who share the goals of RESPIRE across the globe. To facilitate this RESPIRE is also developing a 
Methodology Forum. This will be the interactive web-based platform that will enable delivery of all the 
methodological interaction required to support the RESPIRE projects and the RESPIRE Methodology 
Academy.
The data science elements are more concerned with building solutions across the RESPIRE regions and 
Programmes, specifically establishing the requirements for efficient and large scale projects which in gen-
eral will re-use existing data. This includes specifying arrangements for data sharing and the safe and ef-
ficient processing of routine data. First it must be established what relevant infrastructure and staff re-
source exists, in respect of data science focussed ambitions (eg, using routine local or national data to 
better design randomised trials; using routine data for trial outcomes; and using routine data for long term 
follow-up; and so on) and hence assessing what additional infrastructure and training is required to re-
alise such data science focussed projects in a sustainable way. The overall aim is then to leverage the RE-
SPIRE projects to create and sustain data science-based solutions to design and deliver efficient projects 
(including randomised controlled trials) that make a worthwhile difference quickly to the local people. 
The Unit will address these issues in such a way that the improved infrastructure and increased staff ca-
pacity and knowledge gained can readily be applied to a wide range of non-respiratory conditions ie, be-
yond the scope of RESPIRE.
PROGRESS TO-DATE
Topics for research projects have been identified by the RESPIRE partners in LMICs, who are taking the 
lead in developing detailed research proposals with inputs from RESPIRE leadership and the rest of the 
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Programme investigators. Experts across the partner countries have debated and agreed the research pri-
orities and the respiratory questions to focus their efforts on. A CHNRI research prioritisation exercise 
was also carried out to inform the prioritisation of funding [16]. To date, RESPIRE has developed two-
rounds of proposals which have been externally peer-reviewed, and assessed against the CHNRI scores, 
before being recommended for funding after open review at the RESPIRE UMC. The results of the CHNRI 
priority setting exercise are presented in a separate paper in this issue [16].
While some projects involve issues that are locally relevant, others have the potential to be conducted 
across multiple centres in more than one RESPIRE country. Current RESPIRE research projects are: (i) 
conducting implementation research on introducing pulse oximetry within routine IMCI services at first-
level health facilities in Bangladesh; (ii) assessing feasibility and acceptability followed by effectiveness of 
bubble continuous positive airway pressure (bCPAP) for treatment of Bangladeshi children with severe 
pneumonia; (iii) studying consequence of RSV infection of young infants in childhood – follow-up of 
children in the ANISA cohort; (iv) testing an innovative approach to improving pneumonia perception 
following exploration of under-five pneumonia and asthma in Pakistan; (v) RESPIRE chronic respiratory 
disease prevalence study (4CCORD); (vi) a feasibility study of prevention, detection and treatment of 
adult lung disease in a poor, rural population in Tamil Nadu; (vii) developing and evaluating interven-
tions at patient and practice level to improve asthma care; and (viii) the Malaysian asthma Hajj project.
Seven other projects have been launched which entail a range of research infrastructure developments. 
These projects are: (i) community use of digital auscultation to improve diagnosis of paediatric pneumo-
nia in Sylhet, Bangladesh; (ii) construction of a computational framework to automatically interpret chest 
x-rays and diagnose pneumonia in Bangladesh; (iii) documentation of pneumonia case management prac-
tices in selected communities in Pakistan; (iv) exploration of pneumonia related policy formation and 
implementation in Pakistan; (v) development of spirometry predictive values for Indian population; (vi) 
assessment of the Accredited Social Health Activist (ASHA) programme’s workload and its determinants 
in India; (vii) exploring the provision of supportive/palliative care for patients with very severe COPD in 
Malaysia.
LOOKING AHEAD: A CALL FOR OTHER GROUPS TO JOIN THE RESPIRE 
COLLABORATION
RESPIRE represents a substantial investment by NIHR which it is hoped will catalyse work within the 
initial 4 partner countries and through so doing unlock increased investments from other agencies and 
donors and national sources so that RESPIRE's wider aims and objectives can be achieved. Equally im-
portantly, RESPIRE will need to build a much larger consortium of international partners if the Unit is to 
succeed in demonstrating a sizeable impact on the global burden of respiratory morbidity and mortality. 
As an initial step towards this RESPIRE hosted a meeting in Edinburgh in 2018 of UK-based research 
projects (many of which are supported by NIHR as Global Health Research Units and Groups) which 
have a focus on global respiratory problems. As well as RESPIRE, representatives attended from the: NIHR 
Global Health Research Unit on Lung Health and TB in Africa (IMPALA), NIHR Global Health Research 
Unit on Mucosal Pathogens (MPRU), NIHR Global Health Research Group on Social Policy and Health 
Inequalities, NIHR Global Health Research Group on Global COPD in Primary Care (Breathe Well), NIHR 
Global Health Research Group on Achieving Control of Asthma in Children In Africa (ACACIA), NIHR 
Global Health Research Group on Addressing Smokeless Tobacco and building Research capacity in south 
Asia (ASTRA); and the CGRF-funded: Lung health in Africa across the life course, A mathematical mod-
eling framework for tuberculosis burden estimation and economic evaluation of pharmaceutical inter-
ventions, and the Tobacco control capacity programme. Not able to attend the initial meeting, but also 
members of the group are: the NIHR Global Health Research Group on Sepsis, NIHR Global Health Re-
search Group on Respiratory Rehabilitation (Global RECHARGE) and the NIHR Global Health Research 
Group on Asthma attacks, causes and prevention study in urban Latin America. This group plans to meet 
regularly so that efforts to tackle global respiratory health challenges can be coordinated and synergised. 
Additional groups from high-, middle- and low-resource settings alike, are invited to join this ambitious 
effort and work with RESPIRE to build a true global collaboration that will address the problem of glob-
al respiratory illnesses.
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